SMARTDM2 vs AGA MASH App

The management of outpatient antihyperglycemic regimens for patients with type 2 diabetes is complicated. This app is designed to synthesize treatment pathway guidelines developed by the American Diabetes Association, the American Association of Clinical Endocrinologists / American College of Endocrinology, and the Emory University Diabetes Council. Based on patient-specific factors that you select, a weighted list of medication options is sorted and presented. Designed for use by healthcare professionals. We have no relationship with nor has the app been endorsed by the American Diabetes Association, the American Association of Clinical Endocrinologists or the American College of Endocrinology. Results from the app should not be considered medical advice: individual patient factors not accounted for in the app may influence management decisions; medical evidence and guidelines may change ahead of updates to the app; regardless of best efforts, errors may be present in the app. Consult your doctor before making any changes to your medication regimen.

American Gastroenterological Association’s MASH Clinical Care Pathway app is for use in any setting where health care professionals care for patients with MASH / MASLD, including primary care, endocrine, obesity medicine and gastroenterology practices. Developed with support by independent medical education grants from Intercept Pharmaceuticals, Inc., Pfizer Inc., Allergan, and Genfit. For more information visit gastro.org.